Mandate

Vinge has advised Lendify in connection with a Swedish securitisation

May 22, 2017 Banking and Finance

Lendify AB (”Lendify”), a P2P-lending platform, has issued SEK 200,000,000 bonds on 30 May 2017 through its wholly-owned subsidiary Lendify Sweden 1 AB (publ).

The bonds have a tenor of three years and an annual interest rate of three-months Stibor + 5 %. The bonds are intended to be listed on the regulated market NDX, operated by Nordic Growth Market AB.

The bonds are backed by a portfolio of promissory notes issued by consumers in Sweden in favour of Lendify. The payment of interest and repayment of principal on the bonds are based on the cashflow from the portfolio. The entire documentation is governed by Swedish law and the collateral is held by Intertrust (Sweden) AB, who is also acting as agent for the bondholders.

Together with the management of the company, Carnegie Investment Bank AB (publ) as arranger and issuing agent and its legal advisors, Vinge acted for Lendify in the structuring and documentation of the transaction. Vinge’s team consisted of Jonas Johansson, Emma Stuart-Beck, Albert Wållgren, Louise Nordkvist and André Isacson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025